Theratope Anticancer Vaccine Under FDA Review.(report from Biomira Inc. and Merck KGAA)

2001 SEP 18 - (NewsRx.com & NewsRx.net) --

Biomira Inc., (BIOM) and its collaborator, Merck KGaA, announced plans for a meeting with the U.S. Food and Drug Administration (FDA).

The purpose of the meeting is to review the Theratope vaccine regulatory strategy, and agree on the best approach for bringing this product candidate to market. The meeting is expected to take place in early October, 2001. To date, Biomira has conducted all meetings with the FDA regarding the Theratope vaccine.

"This will be the first opportunity for Biomira and Merck KGaA, through its U.S. affiliate, EMD Pharmaceuticals, Inc., to collectively meet with the FDA to review the …